Genprex to Present at Upcoming Investor and Industry Conferences
October 01 2018 - 8:00AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene
therapy company developing a new approach to treating cancer based
upon a novel proprietary technology platform, announced today that
the management team will present at the following upcoming investor
and industry conferences:
Event: The MicroCap ConferenceDate: October 2,
2018Time: 12:00 PM EDTLocation: New York,
NYPresenter: Rodney Varner, Chairman and CEO
Event: BIO Investor ForumDate: October 18,
2018Time: 9:30 AM PDTLocation: San Francisco,
CAPresenter: Dr. Julien Pham, President and COO
About Genprex™, Inc.Genprex, Inc. is a clinical stage
gene therapy company developing a new approach to treating cancer,
based upon a novel proprietary technology platform, including
Genprex’s initial product candidate, Oncoprex™ immunogene therapy
for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance.
For more information, please
visit www.genprex.com or www.facebook.com/genprexinc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181001005321/en/
Media:James HeinsICR
Healthcare203-682-8251James.Heins@icrinc.comorInvestors:Stephanie
CarringtonICR
Healthcare646-277-1282Stephanie.Carrington@icrinc.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024